- Sweden’s EQT AB and Goldman Sachs Group Inc’s GS investment arm are reportedly negotiating the acquisition of contract-research organization Parexel International Corp for nearly $9 billion, including debt.
- Parexel offers a suite of biopharmaceutical services for clinical trials to regulatory, consulting, and market access.
- Currently, Pamplona Capital Management owns Parexel.
- According to Wall Street Journal, a sale to EQT and Goldman could be completed this week, assuming talks don’t fall apart, the people said.
- The business had drawn interest from both private equity and strategic bidders.
- Price Action: GS shares closed at $374.99 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
